![John Fukuto](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Fukuto
Corporate Officer/Principal chez Cardioxyl Pharmaceuticals LLC
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Douglas Cowart | M | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | 19 ans |
Kimberly McCutcheon Jablonski | F | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Jeff Bank Clark | M | 67 |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Peter Thompson | M | 64 |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Robert J. Garland | M | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Gary L. Stiles | M | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Michael Barrett | M | 81 |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Shi Yin Foo | M | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | 11 ans |
Ronald Borchardt | M | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Michael Givertz | M | - |
Cardioxyl Pharmaceuticals LLC
![]() Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 10 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- John Fukuto
- Réseau Personnel